Suppr超能文献

人工智能驱动的临床试验的进展、陷阱与影响。

Progress, Pitfalls, and Impact of AI-Driven Clinical Trials.

作者信息

Wilczok Dominika, Zhavoronkov Alex

机构信息

Duke University, Durham, North Carolina, USA.

Insilico Medicine US Inc, Cambridge, Massachusetts, USA.

出版信息

Clin Pharmacol Ther. 2025 Apr;117(4):887-890. doi: 10.1002/cpt.3542. Epub 2024 Dec 25.

Abstract

Since the deep learning revolution of the early 2010s, significant efforts and billions of dollars have been invested in applying artificial intelligence (AI) to drug discovery and development (AIDD). However, despite high expectations, few AI-discovered or AI-designed drugs have entered human clinical trials, and none have achieved clinical approval. In this perspective, we examine the challenges impeding progress and highlight opportunities to harness AI's potential in transforming drug discovery and development.

摘要

自21世纪10年代初的深度学习革命以来,人们在将人工智能(AI)应用于药物发现与开发(AIDD)方面投入了大量精力和数十亿美元。然而,尽管寄予厚望,但很少有通过人工智能发现或设计的药物进入人体临床试验,且无一获得临床批准。从这个角度来看,我们审视了阻碍进展的挑战,并强调了利用人工智能潜力来变革药物发现与开发的机遇。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd11/11924158/843c954bd6d2/CPT-117-887-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验